JP Morgan Maintains Overweight on Cellebrite DI, Lowers Price Target to $15
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
JP Morgan analyst Brian Essex maintains Cellebrite DI (NASDAQ:CLBT) with a Overweight and lowers the price target from $16 to $15.
JP Morgan analyst Brian Essex maintains Cellebrite DI (NASDAQ:CLBT) with a Overweight and lowers the price target from $16 to $15.